Observation of short-term efficacy of bronchial arterial chemoembolization combined with anlotinib for treatment of advanced non-small cell lung cancer
10.3760/cma.j.cn115355-20210521-00223
- VernacularTitle:支气管动脉化疗栓塞联合安罗替尼治疗晚期非小细胞肺癌近期效果观察
- Author:
Wenhui WANG
1
;
Xuhua DUAN
;
Hao LI
;
Manzhou WANG
;
Fangzheng LI
;
Pengfei CHEN
;
Wenze XU
;
Jianzhuang REN
;
Xinwei HAN
Author Information
1. 郑州大学第一附属医院介入科，郑州 450052
- Keywords:
Carcinoma, non-small cell lung;
Bronchial arteies;
Chemoembolization, therapeutic;
Anlotinib;
Treatment outcome
- From:
Cancer Research and Clinic
2021;33(12):908-912
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the short-term efficacy and safety of bronchial arterial chemoembolization (BACE) combined with anlotinib for treatment of advanced non-small cell lung cancer (NSCLC).Methods:The clinical data of 14 patients with advanced NSCLC in the First Affiliated Hospital of Zhengzhou University from June 2018 to March 2019 were retrospectively analyzed. The short-term efficacy and adverse reactions of BACE combined with anlotinib hydrochloride were evaluated.Results:All patients successfully received BACE treatment twice. The median follow-up time was 19 months (8-26 months). The objective response rate (ORR) of patients at 1, 3 and 6 months after the first treatment was 100.0% (14/14), 71.4% (10/14) and 57.1% (8/14), and the disease control rate (DCR) was 100.0% (14/14), 92.8% (13/14) and 78.6% (11/14), respectively. The median progression-free survival (PFS) time was 9.5 months (95% CI 9.0-17.3 months), and the 6-month and 12-month PFS rates were 78.6% and 28.6%, respectively. The median overall survival (OS) time was 19.0 months (95% CI 18.4-23.1 months), and the 6-month and 12-month OS rates were 100.0% and 85.7%, respectively. Anlotinib hydrochloride-related adverse reactions included hand-foot syndrome [42.9% (6/14)], fatigue [35.7% (5/14)], hypertension [35.7% (5/14)], oral mucositis [28.6% (4/14)], hemoptysis [28.6% (4/14)], elevated aminotransferases [21.4% (3/14)] and diarrhea [14.3% (2/14)]. There were no grade ≥3 adverse reactions. Conclusion:BACE combined with anlotinib is safe and effective for treatment of advanced NSCLC, and the short-term clinical efficacy is satisfactory.
